Tech Company Financing Transactions
Centessa Pharmaceuticals Funding Round
On 10/5/2021, Centessa Pharmaceuticals received $300 million in funding from Oberland Capital.
Transaction Overview
Company Name
Announced On
10/5/2021
Transaction Type
Debt
Amount
$300,000,000
Round
Undisclosed
Investors
Oberland Capital (Andrew Rubinstein)
Proceeds Purpose
This financing will allow us to further scale up our development activities and provide enhanced balance sheet flexibility for pipeline expansion.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA 02114
USA
Cambridge, MA 02114
USA
Phone
Website
Email Address
Overview
Centessa Pharmaceuticals Limited is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Saurabh Saha
Chief Financial Officer
Marella Thorell
Chief Financial Officer
Gregory Weinhoff
Chief Medical Officer
Antoine Yver
Chief Technical Officer
Thomas Templeman
VP - Administration
David Chao
VP - General Counsel
Iqbal Hussain
VP - Regulatory Affairs
Tia Bush
Browse more venture capital transactions:
Prev: 10/2/2021: Presidio Identity venture capital transaction
Next: 10/5/2021: Ziply Fiber venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs